Key Product Details
Structure / Form
Accession # O75023.1
N-terminal Sequence Analysis
Predicted Molecular Mass
When Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera (Catalog # 10410-T4) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (Catalog # 914-AN) binds with an ED50 of 0.03-0.24 μg/mL.
Scientific Data Images for Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein, CF
Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein Binding ActivityWhen Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera (Catalog # 10410-T4) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Angiopoietin-like 7 (Catalog # 914-AN) binds with an ED50 of 0.03-0.24 µg/mL.
Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein SDS-PAGE2 μg/lane of Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera (Catalog # 10410-T4) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 85-105 kDa and 170-210 kDa, respectively.
Formulation, Preparation and Storage
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
LIR8, also known as CD85c and LILRB5, belongs to the Leukocyte immunoglobulin-like receptors (LILR) family of transmembrane glycoproteins involved in regulating immune responses (1,2). There are at least thirteen LILR family members and are divided into activating (LILRA) or inhibiting (LILRB) molecules (1,2). Mature human LIR8 consists of an extracellular domain (ECD) with four Ig-like domains, a transmembrane segment, and a cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). Alternative splicing of human LIR8 generates at least 2 isoforms, one lacking the second Ig-like domain. The LILR family appears to be primate-specific receptors in terms of sequence homology. LIR8 is expressed on NK cells and in the tryptic granules of mast cells and negatively regulates immune cell activation (3, 4). It is present on the mast cell surface following cell activation and degranulation (4). Activated mast cells may also release soluble forms of LIR8 (3). LIR8 has also been shown to be expressed on T cells and induce CD8+ T cell proliferation (5). Consistent with the demonstrated binding of LILRB2 to Angiopoietin-like 2 and 5 (6), R&D Systems in-house testing indicates that LIR8 binds to Angiopoietin-like 7. Recently, a common missense variant of LIR8 was found to be associated with statin intolerance and myalgia (7).
- Brown, D. et al. (2004) Tissue antigens. 64:215.
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
- Hogan, H. E. et al. (2016) Sci Rep. 6:21780.
- Zheng, J. et al. (2012) Nature 485:656.
- Siddigui, M. et al. (2017) Eur. Heart J. 38:3569.
Product Specific Notices for Recombinant Human LILRB5/CD85c/LIR-8 Fc Chimera Protein, CF
For research use only